Comparison of whole slide image–based deep learning algorithms and genomic classifiers for assessing the risk of prostate cancer metastasis in surgically treated patients.

Authors

null

Lia DePaula Oliveira

Johns Hopkins University, Baltimore, MD

Lia DePaula Oliveira , Eric Erak , Adrianna Mendes , Aditya Vartak , Nilanjan Chattopadhyay , Saikiran Bonthu , Uttara Joshi , Chaith Kondragunta , Nitin Singhal , Angelo M De Marzo , Tamara L. Lotan

Organizations

Johns Hopkins University, Baltimore, MD, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins Hospital, Baltimore, MD, AIRA Matrix, Thane, India, Johns Hopkins University School of Medicine, Baltimore, MD

Research Funding

No funding sources reported

Background: Genomic classifiers improve post-radical prostatectomy (RP) risk stratification compared to conventional clinical-pathologic parameters, but are tissue-destructive and expensive. In contrast, artificial intelligence algorithms utilizing diagnostic hematoxylin and eosin (H&E)-stained slides for risk stratification conserve tissue and could be made widely available at point-of-care. We compared the predictive output of a deep learning-based algorithm applied to H&E-stained whole slide images (WSI) of prostate tumors to commercial genomic classifiers such as Decipher and Prolaris in three diverse RP cohorts with follow-up for metastasis. Methods: We used subsets of three previously published Johns Hopkins RP cohorts with available genomic classifier data. The Natural History Cohort (n=249, Decipher test, PMID: 26058959) and Case-Cohort (n=210, Prolaris CCP test, PMID: 36006048) both utilized a case-cohort design on the outcome of metastasis and consisted of predominantly self-identified White patients, while the Race Cohort (n=93, Decipher test, PMID: 31969336) included only self-identified Black patients with clinical follow-up. For each cohort, a single representative H&E-stained slide from the dominant tumor nodule at RP was scanned. The DL algorithm utilized tumor detection in H&E-stained WSI followed by a classification model to predict metastasis, with or without clinical parameters (age, race, pre-operative PSA, pathologic T- and N-stage, and margin status). The algorithm was trained (n=197) and validated (n=52) on patients from Natural History Cohort and tested on the Race Cohort and Case-Cohort. Harrell’s C-indices based on unadjusted Cox models for time to metastasis were evaluated. Results: The C-index for the WSI-based deep learning algorithm on the Natural History Cohort validation subset was 0.766 (95% confidence interval [CI]: 0.730-0.802) compared to 0.732 (95% CI:0.698-0.766) for the Decipher score. The C-index for WSI-based deep learning algorithm in the Race Cohort was 0.804 (95% CI: 0.790-0.818) compared to 0.724 (95% CI: 0.721-0.726) for the Decipher score. The C-index for the WSI-based deep learning algorithm in the Case-Cohort was 0.840 (95% CI: 0.829-0.851) compared to 0.801 (95% CI: 0.800-0.802) for the Prolaris CCP score. The C-index values for the deep learning algorithm utilizing WSI plus clinical-pathologic parameters were 0.836 (95% CI: 0.796-0.876), 0.882 (95% CI: 0.869-0.894), and 0.890 (95% CI: 0.878-0.901) for the Natural History Cohort, Race-Cohort, and Case-Cohort, respectively. Conclusions: DL algorithms utilizing WSI with or without clinical-pathologic parameters outperform currently employed genomic classifiers for the prediction of metastasis. Validation in additional multi-institutional and racially diverse cohorts is underway.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Other

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 344)

DOI

10.1200/JCO.2024.42.4_suppl.344

Abstract #

344

Poster Bd #

P13

Abstract Disclosures

Similar Abstracts

First Author: Lia DePaula Oliveira

First Author: Edward Christopher Dee

First Author: Corbin J. Eule

Abstract

2024 ASCO Genitourinary Cancers Symposium

Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.

First Author: Grace G Kim